614.60
+0.80%
Close of 9 Nov 2026, in INR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Indegene
Its shares trade on NSE under the ticker INDGN.NS. It has been listed since 13 May 2024. In the fiscal year to 31 March 2026, it reported revenue of ₹35.10bn and net income of ₹4.01bn. At that date it held total assets of ₹46.20bn and shareholders' equity of ₹31.39bn.
Indegene Ltd is a IN-based company operating in industry. The company is headquartered in Bangalore, Karnataka. The company went IPO on 2024-05-13. Indegene Limited is a life sciences commercialization company. The company provides digital-led commercialization services for the life sciences industry, including biopharmaceutical, emerging biotech, and medical devices companies, that assist them with drug development and clinical trials, regulatory submissions, pharmacovigilance and complaints management, and the sales and marketing of their products. Its Omnichannel Activation solutions help life sciences companies leverage a digital first approach for optimizing the last-mile promotion of biopharmaceutical products and medical devices to healthcare professionals across multiple channels. Its Enterprise Commercial Solutions primarily involves assisting life sciences companies with their digital marketing operations. Under its Enterprise Medical Solutions, it establishes centers of excellence to consolidate large scale regulatory and medical operations for its clients. The company also offers enterprise clinical solutions and consultancy services.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- N/A
- Industry
- N/A
- Listed since
- 13 May 2024
- Website
- indegene.com ↗
Leadership
Pay as last reported
- Mr. Manish GuptaExecutive Chairman of the Board, Chief Executive Officer, since 2000
- Mr. Suhas PrabhuChief Financial Officer
- Dr. Sanjay ParikhExecutive Vice President, Executive Director, since 2002
- Mr. Anand NijegalExecutive Vice President - Global Operations
- Ms. Srishti KaushikCompliance Officer, Company Secretary
- Mr. Viveksheel GhaiExecutive Vice President - Enterprise Commercial Solutions of Indegene, Inc.
- Mr. Gaurav KapoorExecutive Vice President of Indegene, Inc.
- Mr. Sameer LalSenior Vice President - Business Development of Indegene, Inc.
- Mr. Neeraj BharadwajNon-Executive Nominee Director
- Mr. Mark DzialgaNon-Executive Nominee Director
- Dr. Rajesh NairNon-Executive Director, President of Indegene, Inc., since 1998
- Mr. Pravin Bhadya RaoNon-Executive Independent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Indegene Ltd provides digital-led commercialization services for the life sciences industry.
- Omnichannel Activation solutions help optimize last-mile promotion of biopharmaceutical products.
- Enterprise Medical Solutions establishes centers of excellence for regulatory operations.
Weaknesses
- The company operates in a single industry without diversification.
- Indegene Ltd is headquartered in Bangalore, Karnataka, India.
- The business relies heavily on drug development and clinical trials.
Opportunities
- Emerging biotech companies can leverage digital first approaches for growth.
- Medical devices companies may utilize sales and marketing consultancy services.
- Pharmacovigilance and complaints management offer expansion potential for clients.
Threats
- Regulatory submissions require strict compliance with evolving health standards.
- Clinical trials involve significant time and resource commitments.
- Life sciences commercialization faces intense competition in the market.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.